Table 1 Baseline characteristics of patients

From: High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

Number of patients 57
Age (years)
 Median 64
 Range 22–80
 % >60 years 61%
Duration of CR1 (months)
 Median 10
Cytogenetics
 Known 56/57
 Favorable 0
 Intermediate risk 44 (78%)
 Poor risk 12 (22%)
 Unknown 1
  1. Abbreviation: CR, complete remission.